Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk

Abstract

Aim: Chronic lymphocytic leukemia (CLL) has been shown to cluster in families. First-degree relatives of individuals with CLL have an ~8 fold increased risk of developing the malignancy. Strong heritability suggests pedigree studies will have good power to localize pathogenic genes. However, CLL is relatively rare and heterogeneous, complicating ascertainment and analyses. Our goal was to identify CLL risk loci using unique resources available in Utah and methods to address intra-familial heterogeneity.

Methods: We identified a six-generation high-risk CLL pedigree using the Utah Population Database. This pedigree contains 24 CLL cases connected by a common ancestor. We ascertained and genotyped eight CLL cases using a high-density SNP array, and then performed shared genomic segment (SGS) analysis - a method designed for extended high-risk pedigrees that accounts for heterogeneity.

Results: We identified a genome-wide significant region (P = 1.9 × 10^-7, LOD-equivalent 5.6) at 2q22.1. The 0.9 Mb region was inherited through 26 meioses and shared by seven of the eight genotyped cases. It sits within a ~6.25 Mb locus identified in a previous linkage study of 206 small CLL families. Our narrow region intersects two genes, including CXCR4 which is highly expressed in CLL cells and implicated in maintenance and progression.

Conclusion: SGS analysis of an extended high-risk CLL pedigree identified the most significant evidence to-date for a 0.9 Mb CLL disease locus at 2q22.1, harboring CXCR4. This discovery contributes to a growing literature implicating CXCR4 in inherited risk to CLL. Investigation of the segregating haplotype in the pedigree will be valuable for elucidating risk variant(s).

Keywords

Gene-mapping / chronic lymphocytic leukemia (CLL) / linkage / CXCR4 / shared genomic segment (SGS) / pedigree / Utah Population Database (UPDB)

References

[1] Chronic lymphocytic leukemia - Cancer Stat Facts. Available from: https://seer.cancer.gov/statfacts/html/clyl.html. [Last accessed on 21 May 2021]

[2] GoldinLR,LiX.Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database.Blood2004;104:1850-4

[3] KerberRA.A cohort study of cancer risk in relation to family histories of cancer in the Utah population database.Cancer2005;103:1906-15

[4] SlagerSL,deSanjose S.Genetic susceptibility to chronic lymphocytic leukemia.Semin Hematol2013;50:296-302 PMCID:PMC3834539

[5] GoldinLR,SgambatiM.A genome scan of 18 families with chronic lymphocytic leukaemia.Br J Haematol2003;121:866-73

[6] SellickGS,AllinsonR.A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci.Am J Hum Genet2005;77:420-9 PMCID:PMC1226207

[7] SellickGS,WildRW.A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia.Blood2007;110:3326-33 PMCID:PMC2200912

[8] RavalA,ByrdJC.Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.Cell2007;129:879-90 PMCID:PMC4647864

[9] FullerSJ,McKinnonL.Analysis of a large multi-generational family provides insight into the genetics of chronic lymphocytic leukemia.Br J Haematol2008;142:238-45

[10] GoldinLR,RotunnoM.Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibility.Blood2016;128:2261-3 PMCID:PMC5095758

[11] SpeedyHE,ChubbD.Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.Blood2016;128:2319-26 PMCID:PMC5271173

[12] BlackburnNB,BanksA.Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies.Blood2017;130:86-8 PMCID:PMC5813724

[13] BrownJR,TesarB.Germline copy number variation associated with Mendelian inheritance of CLL in two families.Leukemia2012;26:1710-3

[14] HansonHA,MadsenMJ.Family study designs informed by tumor heterogeneity and multi-cancer pleiotropies: the power of the Utah Population Database.Cancer Epidemiol Biomarkers Prev2020;29:807-15 PMCID:PMC7168701

[15] WallerRG,WeiX.Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk.PLoS Genet2018;14:e1007111 PMCID:PMC5794067

[16] GlennMJ,DavisE.Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees.Blood Cancer J2019;9:25 PMCID:PMC6391432

[17] KnightS,AbelHJ.Shared genomic segment analysis: the power to find rare disease variants.Ann Hum Genet2012;76:500-9 PMCID:PMC3879794

[18] AutonA,DurbinRM.The 1000 Genomes Project ConsortiumA global reference for human genetic variation.Nature2015;526:68-74 PMCID:PMC4750478

[19] PurcellS. PLINK 1.9. Available from: https://www.cog-genomics.org/plink/1.9/. [Last accessed on 21 May 2021]

[20] ChangCC,TellierLC,PurcellSM.Second-generation PLINK: rising to the challenge of larger and richer datasets.Gigascience2015;4:7 PMCID:PMC4342193

[21] WiggintonJE,AbecasisGR.A note on exact tests of Hardy-Weinberg equilibrium.Am J Hum Genet2005;76:887-93 PMCID:PMC1199378

[22] GraffelmanJ.The mid p-value in exact tests for Hardy-Weinberg equilibrium.Stat Appl Genet Mol Biol2013;12:433-48

[23] ThomasA,FarnhamJM,Cannon-AlbrightLA.Shared genomic segment analysis. Mapping disease predisposition genes in extended pedigrees using SNP genotype assays.Ann Hum Genet2008;72:279-87 PMCID:PMC2964273

[24] MatiseTC,ChenW.A second-generation combined linkage physical map of the human genome.Genome Res2007;17:1783-6 PMCID:PMC2099587

[25] LanderE.Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results.Nat Genet1995;11:241-7

[26] UhlénM,HallströmBM.Proteomics. Tissue-based map of the human proteome.Science2015;347:1260419

[27] ThulPJ,WikingM.A subcellular map of the human proteome.Science2017;356:eaal3321

[28] The Human Protein Atlas. Available from: https://www.proteinatlas.org/. [Last accessed 21 May 2021]

[29] Assays and annotation - The Human Protein Atlas. Available from: https://www.proteinatlas.org/about/assays+annotation#hpa_rna. [Last accessed 21 May 2021]

[30] MöhleR,BautzF.Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1).Leukemia1999;13:1954-9

[31] BurgerJA.Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells.Leuk Lymphoma2002;43:461-6

[32] SchmidtJ,SchindlerN.MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.Br J Haematol2015;169:795-803

[33] GhobrialIM,StensonMJ.Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.Mayo Clin Proc2004;79:318-25

[34] GanghammerS,HuttererE.Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.Haematologica2016;101:e99-102 PMCID:PMC4815737

[35] IshibeN,JilaniIB,MartiGE.CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not.Blood2002;100:1100-1

[36] PuenteXS,Valdés-MasR.Non-coding recurrent mutations in chronic lymphocytic leukaemia.Nature2015;526:519-24

[37] AcunzoM,WernickeD.Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene.Blood2014;124:259-62 PMCID:PMC4093682

[38] Redondo-MuñozJ,TeixidóJ.Molecular players in hematologic tumor cell trafficking.Front Immunol2019;10:156 PMCID:PMC6372527

[39] KristonC,MárkÁ.In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment.Ann Hematol2018;97:2145-52

[40] Hacken E, Burger JA. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.Pharmacol Ther2014;144:338-48

[41] PavlasovaG,SedaV.Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.Blood2016;128:1609-13 PMCID:PMC5291297

[42] MartiniV,FrezzatoF.Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.Br J Haematol2017;178:81-93

[43] KashyapMK,JonesH.Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.Oncotarget2016;7:2809-22 PMCID:PMC4823073

[44] SecchieroP,RimondiE.The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.Oncotarget2017;8:59235-45 PMCID:PMC5601728

[45] ShaimH,HarrisD.The CXCR4-STAT3-IL-10 pathway controls the immunoregulatory function of chronic lymphocytic leukemia and is modulated by lenalidomide.Front Immunol2017;8:1773 PMCID:PMC5775272

[46] TreonSP,MeidK.Ibrutinib in previously treated Waldenström's macroglobulinemia.N Engl J Med2015;372:1430-40

[47] ChatterjeeS,NimmagaddaS. The intricate role of CXCR4 in cancer. In: Pomper MG, Fisher PB, editors. Emerging applications of molecular imaging to oncology. Amsterdam: Elsevier; 2014. p. 31-82.

[48] ScalaS.Molecular pathways: targeting the CXCR4-CXCL12 axis--untapped potential in the tumor microenvironment.Clin Cancer Res2015;21:4278-85

[49] LeeY,JooJ.Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.Carcinogenesis2013;34:307-13

[50] EnjuanesA,BoschF.Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia.Cancer Res2008;68:10178-86

[51] Crowther-SwanepoelD,DyerMJ.Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia.Blood2009;114:4843-6

[52] MilanesiS,BorroniEM.Aberrant CXCR4 signaling at crossroad of WHIM syndrome and Waldenstrom's macroglobulinemia.Int J Mol Sci2020;21:5696 PMCID:PMC7460815

[53] TiaoG,TauschE.Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia.Blood2017;130:2443-4 PMCID:PMC5709789